0 rating

Prognosis

Brettschneider J, Jaskowski TD, Tumani H et al.

University of Ulm, Ulm, Germany.

 J Neuroimmunol 2009;217:95–101.

Editor’s note:The search for a reliable biomarker for multiple sclerosis (MS), and in particular a biomarker for the different subtypes of MS, continues. Several agents, including myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP), have been suggested in the past for this role (J Neurol Sci 2007;259:21–6), particularly as markers for conversion to clinically definite MS from a clinically isolated syndrome, but subsequent analyses have failed to show a convincing association (N Engl J Med 2007;356:371–8). The advantages of a biomarker that can be obtained from a simple blood sample remains appealing, and other agents that can be detected in the serum are therefore being sought.

Return to top

LATEST ARTICLES